ong-term study of SMP-862 in patients with paediatric type 2 diabetes mellitus
Phase 3
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-jRCT2080221475
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients who have undergone diet and exercise therapy prior to initiation of treatment
- HbA1c immediately prior to enrolment is >= 7.0% etc.
Exclusion Criteria
- Patients receiving insulin therapy
- Patients with moderate or severe renal dysfunction
- Patients with severe hepatic dysfunction etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c<br>Final visit
- Secondary Outcome Measures
Name Time Method Glycoalbumin<br>Final visit